Physician profile
David Berkower
NPI 1043324429
$3,466.15
in general payments reported to CMS, 2019-2025
30 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $327 · 2021: $592 · 2022: $252 · 2023: $877 · 2024: $655 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,849.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $977.09 | 2019-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $852.55 | 2019-2025 | Xtampza |
| Abbvie INC. | $196.72 | 2021-2022 | |
| Almatica Pharma LLC | $186.80 | 2021-2023 | Gralise |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.86 | 2019-2023 | Relistor |
| Pfizer INC. | $141.59 | 2019-2021 | |
| Horizon Therapeutics Plc | $96.80 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $82.48 | 2019-2021 | |
| Redhill Biopharma INC. | $79.02 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $76.48 | 2023-2024 | Horizant, Horizant |
| Medtronic, INC. | $72.56 | 2023 | Intellis Adaptivestim |
| Valinor Pharma, LLC | $60.50 | 2023 | Movantik |
| Daiichi Sankyo INC. | $50.81 | 2019 | |
| Virtus Pharmaceuticals LLC | $49.53 | 2021 | |
| Ibsa Pharma INC. | $47.57 | 2023-2024 | Tirosint, Licart, Tirosint |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $40.73 | 2021 | |
| Tonix Medicines, INC. | $40.29 | 2025 | Tonmya |
| Boston Scientific Corporation | $32.69 | 2024 | |
| Medtronic USA, INC. | $32.02 | 2019 | |
| Zyla Life Sciences, INC. | $31.70 | 2019-2020 | |
| Protega Pharmaceutials INC | $29.85 | 2025 | Roxybond |
| Hikma Pharmaceuticals USA | $19.50 | 2021 | |
| Forte Bio-Pharma LLC | $18.56 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.82 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $16.05 | 2025 | |
| Electronic Waveform Lab, INC. | $15.45 | 2019 | |
| Assertio Therapeutics, INC. | $13.92 | 2019 | |
| Allergan, INC. | $13.75 | 2020 | |
| Tersera Therapeutics LLC | $12.89 | 2019 | |
| Pacira Therapeutics, INC. | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Berkower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.